Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from AbbVie

This Investor Is Making Moves In Abbvie, Chipotle And Palo Alto Stock: Here's What He's Buying, What He's Selling

Virtus Investment Partners' Joe Terranova is shaking up his portfolio on Wednesday.

Benzinga

Check Out What Whales Are Doing With ABBV

Someone with a lot of money to spend has taken a bullish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

This Is What Whales Are Betting On AbbVie

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 30 strange trades.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Analyst Ratings For AbbVie

AbbVie (NYSE:ABBV) has observed the following analyst ratings within the last quarter:

Benzinga

Top-Rated AbbVie Stock Hits Record High As It Looks To Expand A Decades-Old Solution

AbbVie stock popped Tuesday after announcing promising test results that could expand use of a treatment for blurry vision.

Investors Business Daily

5 Healthcare Stocks Likely to Withstand a Recession

The healthcare industry has attracted massive investor interest since the onset of the COVID-19 pandemic and could remain in the limelight as COVID cases surge again and necessitate the need for more COVID shots. In addition, the healthcare sector is known to withstand recessions relatively well. So, with several analysts…

StockNews.com

AbbVie Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 39 strange trades.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

AbbVie Whale Trades Spotted

Someone with a lot of money to spend has taken a bearish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Stocks That Drive This Fund's Defiance Of Market Downturn

Retirement planning is a challenge for mutual fund shareholders these days. But this portfolio has defied the market's year-to-date swoon.

Investors Business Daily

Looking At AbbVie's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 48 strange trades.

Benzinga

The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

This Is What Whales Are Betting On AbbVie

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 16 strange trades.

Benzinga

AbbVie, Gedeon Richter Join Forces To Develop Dopamine Receptor Modulators For Neuropsychiatric Diseases

AbbVie Inc (NYSE: ABBV) and Gedeon Richter Plc have

Benzinga

AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar

Alvotech Holdings S.A. has

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Executives Sell More Than $47M Of 5 Stocks

Although the Bank of Canada raised its key lending rate to 0.5% on Wednesday, there were a few notable insider trades.

Benzinga

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 5.52% on an annualized basis.

Benzinga

The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution

Here's a roundup of top developments in the biotech space over the last 24 hours:

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Looking At AbbVie's Recent Whale Trades

Benzinga

AbbVie Files Imbruvica US Application For Pediatric Patients with Chronic Graft Versus Host Disease

AbbVie Inc (NYSE: ABBV) has

Benzinga

Where AbbVie Stands With Analysts

Over the past 3 months, 9 analysts have published their opinion on AbbVie (NYSE:ABBV) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

What Are Whales Doing With AbbVie

Benzinga

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 5.85% on an annualized basis.

Benzinga

Check Out What Whales Are Doing With ABBV

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 22 strange trades.

StockNews.com

3 Warren Buffett Stocks to Buy in February: DaVita, Bristol Myers Squibb, and AbbVie

Warren Buffett’s value investing strategy has paid off, as its investment firm Berkshire Hathaway (BRK.A) has outperformed the broader market. Recently, the billionaire has become worther than Meta Platforms (FB) founder Mark Zuckerberg. Hence, we believe that the Berkshire Hathaway holdings AbbVie (ABBV), Bristol-Myers Squibb (BMY), and DaVita (DVA) might…

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.